BACKGROUND AND AIM: The aim of this study was to estimate the serum levels of endothelin-1 (ET-1) and nitric oxide (NO) and to analyze the correlation of their levels with histopathological grading and staging of the liver in patients with chronic hepatitis B (CHB) and C (CHC). METHODS: Eighty-nine patients who were either HBsAg positive (45 CHB patients, 34 inactive carriers (IC)) or had CHC (10 patients) and 36 healthy volunteers as a control group were included in this study. Fifty patients from the CHB (n=43) or CHC (n=7) groups with elevated serum alanine transaminase (ALT) levels underwent a liver biopsy. Histological activity was scored according to Ishak's activity and the fibrotic index. The ET-1 serum concentration was determined with a commercially available ELISA assay kit. Total nitrite was measured by the Griess reaction as an index for NO production. RESULTS: Serum levels of ET-1 and NO were significantly increased in CHB patients (7.67+/-4.00pg/ml and 172.44+/-50.30mumol/l, respectively) compared with the IC group (3.99+/-5.42pg/ml and 114.68+/-32.22mumol/l, respectively) and the control group (3.05+/-0.65pg/ml and 58.61+/-24.18mumol/l, respectively) (p<0.0001). The CHC patients also had significantly higher serum levels of ET-1 (5.92+/-4.24pg/ml) and NO (147.50+/-55.84mumol/l) compared to the control group (p<0.0001 and <0.001, respectively). Linear regression analysis identified that the level of ET-1 was an independent variable that correlated significantly with the stage score (r(2)=0.348, p<0.0001) in CHB patients but there was no correlation in the CHC group. CONCLUSION: ET-1 and NO levels were increased in chronic hepatitis and there was a significant correlation between the ET-1 level and the stage in CHB patients.
BACKGROUND AND AIM: The aim of this study was to estimate the serum levels of endothelin-1 (ET-1) and nitric oxide (NO) and to analyze the correlation of their levels with histopathological grading and staging of the liver in patients with chronic hepatitis B (CHB) and C (CHC). METHODS: Eighty-nine patients who were either HBsAg positive (45 CHB patients, 34 inactive carriers (IC)) or had CHC (10 patients) and 36 healthy volunteers as a control group were included in this study. Fifty patients from the CHB (n=43) or CHC (n=7) groups with elevated serum alanine transaminase (ALT) levels underwent a liver biopsy. Histological activity was scored according to Ishak's activity and the fibrotic index. The ET-1 serum concentration was determined with a commercially available ELISA assay kit. Total nitrite was measured by the Griess reaction as an index for NO production. RESULTS: Serum levels of ET-1 and NO were significantly increased in CHB patients (7.67+/-4.00pg/ml and 172.44+/-50.30mumol/l, respectively) compared with the IC group (3.99+/-5.42pg/ml and 114.68+/-32.22mumol/l, respectively) and the control group (3.05+/-0.65pg/ml and 58.61+/-24.18mumol/l, respectively) (p<0.0001). The CHCpatients also had significantly higher serum levels of ET-1 (5.92+/-4.24pg/ml) and NO (147.50+/-55.84mumol/l) compared to the control group (p<0.0001 and <0.001, respectively). Linear regression analysis identified that the level of ET-1 was an independent variable that correlated significantly with the stage score (r(2)=0.348, p<0.0001) in CHB patients but there was no correlation in the CHC group. CONCLUSION:ET-1 and NO levels were increased in chronic hepatitis and there was a significant correlation between the ET-1 level and the stage in CHB patients.